QBiotics Prospectus - Extension of Closing Date
BRISBANE, 23 October 2026
QBiotics Group Limited (QBiotics or the Company) advises that it has elected to extend the Closing Date for its current Prospectus Offer to 4 December 2026. The extension is designed to allow additional time to engage with prospective investors and for a number of investors to complete their applications. The extension also reflects the rescheduling of the Company’s Middle East investor roadshow, in light of the current situation in the region.
Revised timetable*
The revised timetable is set out below:
|
Date of Original Prospectus lodged with ASIC |
5 August 2026 |
|
Prospectus Date |
12 August 2026 |
|
Opening Date for Application (9:00 am) |
13 August 2026 |
|
Closing Date for Application (5:00 pm AEDT) |
4 December 2026 |
|
Issue and allotment of Shares (Completion of the Offer) |
10 December 2026 |
|
Expected dispatch of holding statements (and any refund payments if applicable) |
11 December 2026 |
*Please note that the above dates are indicative only and may change without notice.1
Terms that are capitalised, but not defined in this announcement have the meaning given to them in the Replacement Prospectus.
Background to the updated timetable
QBiotics lodged a prospectus with the Australian corporate regulator, the Australian Securities and Investments Commission (ASIC) on 5 August 2026 (Original Prospectus) to raise a minimum of $5,000,000 and up to $40,000,000 (Offer) from new and existing shareholders. A replacement prospectus was lodged on 12 August 2026 (Replacement Prospectus) with the offer period commencing on 13 August 2026. QBiotics subsequently lodged the first supplementary prospectus dated 17 September 2026 (First Supplementary Prospectus) and the second supplementary prospectus (Second Supplementary Prospectus) dated 30 September 2026, to be read together with the Replacement Prospectus.
All references to the Indicative Timetable in the Original Prospectus and Replacement Prospectus, as amended by the First Supplementary Prospectus and Second Supplementary Prospectus, are taken to be updated to refer to the updated timetable as shown above.
Accessing the Prospectus
A copy of the Prospectus and related materials is available via the Offer Document box on the following link: https://qbiotics.com/investors/investor-information.
- The dates in the revised timetable above are indicative only and may change without notice. Unless otherwise indicated, all times are stated in Australian Eastern Daylight time. QBiotics reserves the right to vary any and all of the above dates and times without notice including, subject to the Corporations Act, to close the Offer early, to extend a closing date, or to accept late applications or bids, either generally or in particular cases, or to cancel or withdraw the Offer before Settlement, in each case without notifying any recipient of this Prospectus or Applicant. Offers may be made and may be open for acceptances under this Prospectus either generally or in particular cases, including until Completion or, subject to the Corporations Act, thereafter, at the discretion of the Directors.
If the Offer is cancelled or withdrawn before the allocation of Shares, then all Application Monies will be refunded in full (without interest) as soon as possible in accordance with the requirements of the Corporations Act. Investors are encouraged to submit their Applications as soon as possible after the Offer opens.
FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
ABOUT QBIOTICS
QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. Tigilanol tiglate data has been reported via a Phase II clinical trial in soft tissue sarcoma and a Phase II clinical trial in head and neck cancer. These studies demonstrated objective response rates of 82% and 78%, respectively, in injected tumours with most adverse events consistent with the expected local mode of action of the drug and translational research validating immunological responses. Impressive efficacy and safety outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I safety study and efficacy was reported in nine different tumour types. QBiotics is soon to implement a Phase II trial in breast cancer in partnership with Unicancer, the French Federation of cancer centres and is currently exploring the treatment of visceral tumours by tigilanol tiglate in a preclinical study.
QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human Phase I clinical study treating Venous Leg Ulcers.
Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of tigilanol tiglate secured.
QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings in the veterinary environment, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complemented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, small molecule chemistry and translational drug development.
QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.
For more, head to: QBiotics.com or LinkedIn